Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) traded down 2.9% during trading on Thursday . The company traded as low as $28.28 and last traded at $28.65. 49,281 shares were traded during trading, a decline of 36% from the average session volume of 77,342 shares. The stock had previously closed at $29.50.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the stock. William Blair restated an "outperform" rating on shares of Korro Bio in a report on Wednesday, November 13th. Oppenheimer initiated coverage on shares of Korro Bio in a report on Friday, January 10th. They issued an "outperform" rating and a $155.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $115.00 price target on shares of Korro Bio in a research note on Friday, November 22nd. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Korro Bio presently has a consensus rating of "Buy" and a consensus price target of $144.00.
Get Our Latest Analysis on KRRO
Korro Bio Trading Down 8.2 %
The business's 50-day moving average is $37.45 and its two-hundred day moving average is $44.16.
Hedge Funds Weigh In On Korro Bio
A number of hedge funds and other institutional investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS purchased a new stake in shares of Korro Bio during the fourth quarter valued at approximately $53,000. Quest Partners LLC grew its stake in Korro Bio by 172.1% in the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company's stock valued at $59,000 after purchasing an additional 1,124 shares during the period. AlphaQuest LLC increased its position in shares of Korro Bio by 23.2% during the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock valued at $83,000 after purchasing an additional 412 shares during the last quarter. Brown Brothers Harriman & Co. raised its stake in shares of Korro Bio by 251.0% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company's stock worth $95,000 after purchasing an additional 2,041 shares during the period. Finally, Vestcor Inc purchased a new position in shares of Korro Bio in the 3rd quarter worth about $100,000. Hedge funds and other institutional investors own 13.18% of the company's stock.
About Korro Bio
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Featured Stories
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
